Find A Research Study
Study Title: Boceprevir in Subjects with Previously Untreated Chronic HCV Genotype 1
Category: Gastroenterology
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Kris Kowdley
Study Coordinator: Cheryl Saunders
Phone: 206-341-1786
Email: cheryl.saunders@vmmc.org
What is the Boceprevir in Subjects with Previously Untreated Chronic HCV Genotype 1 study?
Who can participate?
What do I have to do as a study participant?
Study Summary:
Patients will undergo 4 weeks of treatment with PegIntron + Ribivirin and will then be given either boceprevir or placebo for an additional 44 weeks.
Detailed Study Description:
Study Design: Interventional, Blinded
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Hepatitis C
Intervention Type: drug
Intervention Name: Boceprevir
Gender: Male and Female
Age group: Interventional
Sponsor: Schering-Plough Research Institute
Other studies in this category include:
Studies currently accepting study participants:
- 5-arm, parallel-group study of the effects on viral kinetics, safety and pharmacokinetics of different dosing regimens of Debio 025 in combination with peginterferon alpha-2a and ribavirin in chronic HCV genotype 1 patients who non-responders to standard
- 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B Virus
- 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B Virus
- A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001
- A Randomized Phase II/III of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
- Abatacept in Treatment of Patient with Active Crohns Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Abatacept in Treatment of Patient with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Boceprevir in Subjects with Previously Untreated Chronic HCV Genotype 1
- Evaluation of PillCam® ESO 2 in Patients with Suspected Esophageal Pathologies
- Liver Disease Registry and Tissue Repository
- RG1068 (Synthetic Human Secretin) – Enhanced MRCP in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis
Studies currently not accepting study participants:
No studies currently listed. Please try another category.